Fleming researchers, in collaboration with GlaxoSmithKline and the London School of Hygiene and Tropical Medicine, developed a novel series of fast-kill agents against malaria. Chemoproteomic analysis also showed that the mechanism through which this fast-kill effect is exhibited is the inhibition of serine/arginine protein kinase 2 (SRPK2), thus rendering this target a tractable approach for developing antimalarial compounds with extremely fast-killing properties. [Pubmed]

DOI: 10.1021/acs.jmedchem.9b01099 

B.S.R.C. "Alexander Fleming"
34 Fleming Street, 16672 Vari, Greece
Contact us - Privacy Policy